NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing | 2022 Evolution Conference

Next generation sequencing and “liquid biopsy” technologies have been increasingly utilized to guide cancer treatment and detect minimal residual disease following treatment, but significant challenges remain before these methodologies can replace traditional methods and have a wider application in clinical practice. In this session, Dr Shayma Kazmi from Penn Medicine highlights some of the most important steps needed to overcome these challenges.
To obtain credit for this CME activity you must watch the full 2022 Evolution Conference Playlist. Information on obtaining CME/CE Credits and MOC points can be found in the playlist description.